Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Spero Therapeutics, Inc. (SPRO) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Spero Therapeutics, Inc. 2017 Stock Incentive Plan, as amended",
"CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION, AS AMENDED OF SPERO THERAPEUTICS, INC.",
"Spero Therapeutics, Inc. 2017 Stock Incentive Plan, as amended"
08/22/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
08/10/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/10/2023 8-K Quarterly results
Docs: "Spero Therapeutics Announces Second Quarter 2023 Operating Results and Provides a Business Update"
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
07/31/2023 8-K Quarterly results
05/11/2023 8-K Quarterly results
Docs: "Spero Therapeutics Announces First Quarter 2023 Operating Results and Provides a Business Update"
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
02/14/2023 SC 13G/A BIOTECHNOLOGY VALUE FUND L P reports a 0% stake in Spero Therapeutics, Inc.
02/14/2023 SC 13G/A Aquilo Capital Management, LLC reports a 0% stake in SPERO THERAPEUTICS, INC.
02/01/2023 8-K Quarterly results
01/20/2023 SC 13D/A GSK PLC reports a 17.8% stake in SPERO THERAPEUTICS, INC.
01/09/2023 8-K Investor presentation
Docs: "Investor Presentation of Spero Therapeutics, Inc.",
"Excerpts from Investor Presentation of Spero Therapeutics, Inc."
11/14/2022 D Form D - Notice of Exempt Offering of Securities:
11/14/2022 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
11/14/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
11/14/2022 8-K Quarterly results
11/14/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/08/2022 8-K Quarterly results
10/03/2022 SC 13G/A Aquilo Capital Management, LLC reports a 9.8% stake in SPERO THERAPEUTICS, INC.
09/22/2022 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr"
09/19/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Spero Therapeutics, Inc. 2017 Stock Incentive Plan, as amended",
"Spero Therapeutics, Inc. 2017 Stock Incentive Plan, as amended"
09/06/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Media Inquiries:"
08/10/2022 8-K Quarterly results
08/10/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/05/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
08/05/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
07/08/2022 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
07/01/2022 8-K Quarterly results
06/27/2022 8-K Quarterly results
06/07/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
05/16/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/03/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy